Drug Trial Radar · NCT05310071
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,027
Actual
Start
Jun 2, 2022
Primary completion
Aug 12, 2024
Study completion Aug 12, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Apr 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Conditions
- Alzheimer's Disease
Interventions
AducanumabDrug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78Time frame: Baseline, Week 78
Locations
265 sites in 16 countries. Site status is shown where the registry gives one.
Gilbert Neurology Partners, PLLC
Gilbert, Arizona
Xenoscience Inc.
Phoenix, Arizona
Banner Alzheimer's Institute
Phoenix, Arizona
Barrow Neurological Institute
Phoenix, Arizona
HonorHealth Neurology
Scottsdale, Arizona
Mayo Clinic Arizona
Scottsdale, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Banner Alzheimer's Institute
Tucson, Arizona
Health Initiatives Research
Fayetteville, Arkansas
Sun Valley Behaivoral Med Center
El Centro, California
Neuropain Medical Center
Fresno, California
Neurology Center of North Orange County
Fullerton, California
Irvine Center for Clinical Research, Inc.
Irvine, California
Mary S. Easton Center for Alzheimer's Disease Research, UCLA
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Stanford Hospital and Clinics
Palo Alto, California
VA Palo Alto Health Care System
Palo Alto, California
Anderson Clinical Research
Redlands, California
Sutter Health-San Francisco
San Francisco, California
University of California San Francisco (PARENT)
San Francisco, California
The Neuron Clinic
San Marcos, California
Syrentis Clinical Research
Santa Ana, California
California Neuroscience Research, LLC
Sherman Oaks, California
Viking Clinical Research Center
Temecula, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Mountain Neurological Research Center
Basalt, Colorado
Yale University
Fairfield, Connecticut
Institute for Neurodegenerative Disorders (IND)
New Haven, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
Research Center for Clinical Studies, Inc.
Norwalk, Connecticut
Howard University Health Sciences
Washington D.C., District of Columbia
Neurology of Central Florida Research Center, LLC
Altamonte Springs, Florida
JEM Research Institute
Atlantis, Florida
Neurology Offices of South Florida, PLLC
Boca Raton, Florida
ECommunity Research, LLC
Boca Raton, Florida
Nova Clinical Research, LLC
Bradenton, Florida
JY Research Institute
Cutler Bay, Florida
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Showing 40 of 265 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.